

GV Investment Fund (Private offer)

Introduction Term Sheet:

A feeder fund to a licensed RFMC/VCC company in Singapore approved by MAS.

There are many undervalued and uncovered potential in SME/startups sector with exponential upside growth opportunities. This is the kind of companies the fund would be considering investing.

The fund is to tap on market trend and opportunity to maximize returns by collectively come together with a team of domain gurus and experts. Diversifying risks to invest into various kinds of projects in different industry sector but limited to the following mandate.

Particularly in fintech, healthcare, med-tech, biotech, blockchain technologies and education sectors.

The propose interest is 2% per annum. Carried interest is 20% on total fund performance after YEAR 2.



FUND SIZE & STRUCTURE

Close-end Fund: Duration is 5 yrs. Renewable every 5 years.

Target ROI : 2% interest on capital & 20% carried interest on profit if any, after year 2

Target deals: 30-60 companies

Investment by invitation and open to Accreditor Investor only Fund size :

S\$10m to S\$200m

Min investment: S\$20,000

Max investment: S\$10m (LP)

Investment sum with S\$500K (Qualified to join Investment committee)

Investment committee: 3 members

VCC Manager/Investor Relations: Janet Lee

Advisor & GP: Dr. Lim KM

Fund & Risks Manager: Dr. Nisha

Annual Fund Management Fee: 2%

Contact: janet@vc-network.org


Fund Objective

- To seek for projects that are able to generate ROI within 12 months to 24 months
- To achieve minimally 10% to 30% nett returns per annum
- To update report on fund performance to member on a annually basis
- To do portfolio re-balancing where necessary by investment team
- To invest into suitable assets as per guidelines or mandate of fund.
- To review investment strategies where necessary

Consideration factors:

- ❖ Innovative & disruptive ideas
- ❖ Solving industry problems
- ❖ Committed & Passionate team
- ❖ Sustainability
- ❖ Scalability
- ❖ Exit strategy

Industry Sector



■ SME Scale up ■ IEO/STO Projects ■ Admin/Marketing cost ■ Pre-IPO/Fund of Funds ■ Startups

FUND MANAGEMENT TEAM:

Dr Nisha Kohli (Fund & Risks Manager/Financial Analyst)

Nisha Kohli is a PhD in Corporate Governance and Valuations and also a chartered accountant with over 18 years of international training, research and consulting experience in the field of Corporate finance, ESG, Startups, Governance and accounting. She is passionate about bringing positive changes in the startup ecosystem. Dr Nisha has partnered for mentoring with incubators like SIIC, Faster Capital and The Entrepreneurship School. She has clients across Asia. Dr Nisha has been helping startups in raising money by performing preliminary due diligence, financial projections, preparation of pitch decks and introducing them to the investors. She is an international partner at the World Business Angel Investment Forum. She also specializes in business valuations and helps scaling companies to raise finance through debt or equity and support organizations in their turnarounds, M&A, Joint Ventures and improving their profitability and liquidity. She is the founder of Nichefin Consulting which provides Impact Measurement of Social Enterprises, ESG/SDG Consulting, financial advisory services to the Corporates. She was awarded Corporate Governance Research Scholar award in 2008 from International Corporate Governance Network for her outstanding research in the field of Corporate Governance.

Ms Janet Lee (VCC Manager/Investor Relations)

Janet Lee is a serial entrepreneur. She is a qualified Associate Financial Consultant with IFPAS and held a Diploma in MS. She studied professional qualification in Association of Accounting Technician, UK (AAT,UK), Corporate Finance (SUSS) and holder of Capital Markets Financial Advisory Services (M1, M5, M6, M8, M9)registered with MAS.

She has spent more than 25 years working in the fields of wealth management, money markets & capital markets with banks & stocks brokering houses inclusive of Citibank, UOB, Phillips Securities, Westcomb Securities & OCBC Securities as a Relationship Manager, Associate Director, Financial Analyst & Stock Broker. She is currently a VC Accelerator & had successfully help a various local SME owners/startups to pitch in China for fundraising & OTC listings matters. In recent years her focus is in ICO listings advisory & fundraising campaign. In the meantime, setting up their own proprietary investment fund.

Her portfolios inclusive of Managed Accounts, Structured Products, Unit Trusts, Corporate Bonds & Notes, Commodities, Dual currency & Forex Trading. Also into Equity sales & trading into various world exchanges, IPO placements, investor relationship management, Private Equity deals, M & A, crowdfunding and alternative investments. Over the years, the assets under her management exceeded S\$20 million with 800+ clientele. In 2018, she successfully helped two local ICO projects listed on Gilbratra Blockchain Exchange (GBX) as a sponsored firm to the exchange.

Dr Lim Kai Meng (GP/ Advisor)

DR. LIM KAH MENG (PhD, Biomedicine) Dr Lim has dedicated a large part of his research focus on molecular biomedicine. He is a strong advocate of cellular wellness and stem cell medicine. For over more than 20 years, he has fervently pursued his scientific interests on bioactive molecules that govern and regulate cellular pathways leading to cellular homeostasis and well being. Besides cellular genetics, he has actively and continuously studied epigenetic mechanisms for which good cellular health could find its basis on. Indeed, embryonic development including prenatal and fetal development are some of the natural processes that fascinates him most. Dr Lim has been credited to be the 'Father of Molecular Edible Bird Nests'. He has researched thoroughly and filed more than 29 patents just on the extraction processes for the bioactive molecules including immunological active bio-molecules from edible bird nests. In addition, he is also known in this region to be the "Father of Molecular Placenta' where he has successfully developed hugely popular products for the commercial world based on placental stem cell extracts. He has since diversified into other stem cell research including products or platforms based on induced pluripotent stem cells for personalized aesthetics as well as therapeutics where he also spearheads clinical trials for specific diseases such as diabetes, psoriasis and dementia. He has also published a paper documenting successful clinical cases for 9 cancer patients in Singapore using high dose intravenous vitamin C. Over the last 20 years, Dr Lim has continually maintained his passion for finding innovative and commercially viable solutions for molecular medicine for cancers, where he has also published at least 3 international peer reviewed scientific papers. Dr Lim is also deep into biomedical research for neuroscience. He has filed for at least 5 patents related to cannabinoids, specifically on medical cannabis but not exclusive to just neurological usage. Besides pharmacological compounds, Dr Lim is also an active researcher for nutraceutical compounds for enhancing neurological functions, optimising bioactive compounds extracted from berries. In the molecular diagnostic space, Dr Lim has earned reasonable credits in optimising methods to successfully use ribonucleic acids or RNAs and micro RNAs (micro ribonucleic acids) as innovative and next generation diagnostic markers for most cancers and chronic diseases in preclinical presentations, and which are currently often undetectable by conventional methods. The last 5 years had also been committed by Dr Lim to fulfill intensive research on using proprietary extracts from genuine porcupine dates to develop as potential platelet biomedicine, which could form an integral and fundamental basis for vascular medicine to alleviate chronic diseases. Commercially, he has successfully developed and invested in at least 7 potentially unicorn start-up companies among his consortium the last decade. An accomplished scientist and established business leader, he was also the recipient for the Singapore award of the 10 outstanding young persons of the world in 2012.